Revascularization of chronic total occlusion coronary artery and cardiac regeneration

Area of Science:

• Cardiology
• Regenerative Medicine

Background:

• Coronary chronic total occlusion (CTO) exacerbates heart failure in ischemic cardiomyopathy.
• Percutaneous coronary intervention (PCI) for CTO improves symptoms but not clinical outcomes compared to optimal medical therapy.
• Physician support for CTO-PCI remains high despite mixed clinical trial results.

Purpose of the Study:

• To review the current status of CTO-PCI in ischemic cardiomyopathy.
• To explore the clinical prospects of cardiac regeneration following CTO-PCI.
• To bridge the gap in understanding the relationship between CTO revascularization and cardiac regeneration.

Main Methods:

• Literature review of randomized controlled trials on CTO-PCI.
• Analysis of experimental studies on cardiac regeneration models.
• Examination of early-stage clinical trials on cell therapy for ischemic cardiomyopathy.

Main Results:

• CTO-PCI improves angina and quality of life but not major adverse cardiac events.
• Cardiac regeneration therapy, including cell therapy, shows potential in reducing scar size, reversing remodeling, and promoting angiogenesis.
• Existing research on CTO revascularization and cardiac regeneration is limited, with experimental models often not reflecting clinical scenarios.

Conclusions:

• Cardiac regeneration therapy presents a promising avenue to enhance outcomes after CTO-PCI in ischemic cardiomyopathy.
• Further research is needed to elucidate the interplay between CTO revascularization and cardiac regeneration strategies.
• Integrating regenerative approaches post-CTO-PCI may offer a novel strategy to improve long-term prognosis for patients with ischemic cardiomyopathy.